Penn Vet BEST1 dog study helps move gene therapy into clinic
Bottom line
Penn Vet researchers say their work in dogs with naturally occurring BEST1 mutations has helped push another inherited retinal disease therapy into human testing. In the newly highlighted study, the team reported that AAV-mediated gene therapy restored retinal structure and function in canine bestrophinopathy, a naturally occurring model that closely mirrors human BEST1-related disease. That preclinical package helped support the human program for OPGx-BEST1, a one-time subretinal gene therapy now in an ongoing Phase 1b/2a clinical trial for adults with Best vitelliform macular dystrophy or autosomal-recessive bestrophinopathy. The trial, listed as NCT07185256, is evaluating safety, tolerability, dose, and early efficacy after treatment in one eye. (med.upenn.edu)
Why it matters: For veterinary professionals, this is another clear example of how naturally occurring disease in dogs can shape human drug development, especially in ophthalmology and gene therapy. Penn’s canine model appears to have offered something rodent models could not: a fovea-like retinal region and disease features that more closely resemble human macular pathology. That makes the work relevant not only as a translational success story, but also as a reminder that veterinary patients and veterinary research programs can play a central role in de-risking advanced therapeutics before they reach people. (vet.upenn.edu)
What to watch: Opus Genetics said it expects 3-month topline data from Cohort 1 in September 2026, which should offer a clearer read on whether the canine findings are translating into broader early human signals. (ir.opusgtx.com)
Key facts
- Therapy
- OPGx-BEST1
- Modality
- AAV-based, one-time subretinal gene therapy
- Target gene
- BEST1
- Indications
- Best vitelliform macular dystrophy and autosomal-recessive bestrophinopathy
- Trial
- NCT07185256
- Phase
- Phase 1b/2a
- Study design
- Open-label, dose-exploring basket trial
- Key preclinical finding
- Gene therapy restored retinal structure and function in dogs with naturally occurring BEST1 mutations
- What to watch
- Opus expects 3-month topline Cohort 1 data in September 2026
A Penn Vet-led gene therapy program for a rare inherited blinding disease has crossed an important translational milestone: after showing retinal rescue in dogs with naturally occurring BEST1 mutations, the related human therapy, OPGx-BEST1, is now in clinical testing. Penn’s Center for Hereditary Retinal Degenerations flagged the advance on July 7, 2026, describing the canine work as critical preclinical evidence supporting FDA clearance to move into human trials. (med.upenn.edu)
The background here matters. BEST1-related inherited retinal diseases, including Best vitelliform macular dystrophy and autosomal-recessive bestrophinopathy, are caused by mutations in the BEST1 gene, which is active in retinal pigment epithelium cells. These disorders can produce retinal lesions, fluid, progressive atrophy, and central vision loss, and there are still no approved treatments. Opus Genetics says the addressable U.S. population is about 8,400 people, while its broader estimate for BEST1-associated disease worldwide is roughly 22,000. (opusgtx.com)
What helped move this program forward was the dog model. Penn researchers have emphasized that canine BEST1 disease reproduces key human features, including pathology in a fovea-like retinal region that mice do not model well. In the Penn materials describing the work, investigators reported that gene augmentation corrected both mild and severe lesions, restored the relationship between photoreceptors and their support cells, and produced durable benefit in treated dogs for as long as six years. The same research effort also examined human patients with BEST1 mutations and found microscopic retinal separation associated with delayed dark adaptation, strengthening the biological rationale for translation. (vet.upenn.edu)
That preclinical work now underpins OPGx-BEST1, an AAV-based, one-time subretinal gene therapy designed to deliver a functional BEST1 gene to retinal pigment epithelium cells. The human study, NCT07185256, is a Phase 1b/2a, open-label, dose-exploring basket trial in adults with BVMD or ARB, with follow-up planned for five years. According to trial and company materials, participants receive treatment in one eye, with investigators tracking safety, tolerability, dose selection, imaging changes, immunogenicity, and early visual outcomes. (clinicaltrials.gov)
The clinical program has already moved beyond simple trial launch. Opus announced in November 2025 that the first participant had been dosed, and by March 2026, early data from the sentinel participant showed favorable short-term safety, no reported ocular or treatment-related adverse events, a 12-letter gain in best-corrected visual acuity, and a 23% reduction in central subfield thickness at three months. In May 2026, the company said Cohort 1 enrollment was complete with five participants, and that full 3-month topline data from the cohort are expected in September 2026. Those are company-reported early findings, so they should be read as preliminary until fuller peer-reviewed data emerge. (retinalphysician.com)
Independent expert commentary specific to this latest milestone was limited in publicly accessible sources, but the broader ophthalmology literature supports why this program is being watched. A JAMA Ophthalmology commentary noted that bestrophinopathies are clinically heterogeneous, spanning different inheritance patterns and phenotypes, which helps explain why careful patient selection and endpoint design matter in early trials. Opus has said that, for participants with dominant disease, it used an in vitro platform to confirm that each mutation was amenable to gene augmentation before enrollment, an important detail for a genetically complex target. (jamanetwork.com)
Why it matters: For veterinary professionals, this story lands on two levels. First, it reinforces the scientific value of naturally occurring canine disease models in areas where anatomy and disease behavior need to mirror human patients more closely than engineered rodent models can. Second, it shows how veterinary ophthalmology can contribute directly to the development path for high-value human therapeutics, from mechanism and imaging endpoints to durability and surgical delivery questions. In a field where gene therapy programs are expensive and technically demanding, that translational role can shape partnerships, funding, and the visibility of academic veterinary research. (vet.upenn.edu)
What to watch: The next inflection point is expected in September 2026, when Opus plans to report 3-month topline Cohort 1 data; after that, attention will likely turn to dose selection, durability, whether early anatomical improvements translate into functional gains across more patients, and how regulators view endpoint development in a small, heterogeneous inherited retinal disease population. (ir.opusgtx.com)